DPP-4 (Dipepitidyl Peptidase-4) inhibitor compound

A compound and selected technology, applied in the field of DPP-4-related diseases, dipeptidyl peptidase IV (DPP-4) inhibitor compounds, can solve GLP-1 inactivation and other problems

Active Publication Date: 2014-05-07
NANJING HUAWE MEDICINE TECH DEV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DPP-4 can rapidly cleave proline or alanine at the second position of th...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DPP-4 (Dipepitidyl Peptidase-4) inhibitor compound
  • DPP-4 (Dipepitidyl Peptidase-4) inhibitor compound
  • DPP-4 (Dipepitidyl Peptidase-4) inhibitor compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073]

[0074] experiment procedure:

[0075] first step:

[0076] Method A

[0077] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), HBTU( 2.27g, 6.0mmol) was added to a 100ml round bottom flask, dissolved with 20ml of DMF, then DIEA (0.78g, 6.0mmol) was added to the reaction solution, and the reaction was stirred at room temperature for 1.5 hours. TLC detection (petroleum ether: ethyl acetate = 4:1), the reaction is over, the reaction solution is added to 10 times the amount of water, a white solid precipitates out, filtered, the filter cake is washed with water, and the solid obtained is dried.

[0078] Method B

[0079] Weigh Boc-(R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid (1.0g, 3.0mmol), anhydrous piperazine (0.26g, 3.0mmol), DCC( 6.0mmol) and HoBt (6.0mmol) were added to a 100ml round bottom flask, dissolved in 20ml DMF, and then DIEA (12.0mmol) was added to the reaction solution, and the reaction was st...

Embodiment 2

[0085] Chemical reaction formula:

[0086]

[0087] Experimental process: The specific experimental process of compound 2 is similar to that of Example 1, refer to Example 1.

[0088] MSm / z(ESI): 613.5[M+Na]

[0089] 1 H-NMR (500MHz, deuterated DMSO): δ7.31~7.38(m,2H), 7.13~7.22(m,2H), 4.01~4.15(m,2H), 4.42(m,1H), 3.67(s ,3H), 2.80~2.91(m.4H), 2.59~2.72(m,4H).

Embodiment 3

[0091] Chemical reaction formula:

[0092]

[0093] Experimental process: The specific experimental process of compound 3 is similar to that of Example 1, refer to Example 1.

[0094] MSm / z(ESI): 539.3[M+H]

[0095] 1 H-NMR (500MHz, deuterated DMSO): δ7.60~7.65(m,4H), 7.31~7.38(m,2H), 7.13~7.22(m,2H), 4.42(m,1H), 4.01~4.15 (m, 2H),, 3.67(s, 3H), 2.80~2.91(m.4H), 2.59~2.72(m, 4H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound as shown in Formula (I) as shown in the specification. The compound, optical isomers, pharmaceutically acceptable inorganic or organic salt, crystal forms, hydrates or solvates of the compound can be used for treating diabetes, particularly non-insulin dependent diabetes, and other diseases related to DPP-4. Definitions of substituents in the general formula (I) are the same as those in the specification.

Description

Technical field [0001] The present invention belongs to the field of organic synthesis, and specifically relates to a novel dipeptidyl peptidase IV (DPP-4) inhibitor compound and its use for treating and preventing diabetes and other diseases related to DPP-4. Background technique [0002] Diabetes mellitus is a chronic metabolic disease caused by various pathogenic factors such as genetic factors, immune dysfunction, microbial infections and their toxins, free radical toxins, and mental factors. It is clinically characterized by high blood sugar. It can be divided into type 1 diabetes (insulin-dependent), type 2 diabetes (non-insulin-dependent), gestational diabetes and other special types of diabetes. Among diabetic patients, type 2 diabetes accounts for about 95%. [0003] At present, the main oral hypoglycemic drugs are: sulfonylureas (SU), biguanides, α-glucosidase inhibitors, non-sulfonylureas insulin secretion drugs and insulin sensitizers: thiazolidinediones. These drugs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D295/185C07C237/20C07D487/04C07D207/08C07C229/34C07D241/04C07D241/42C07C255/29C07C231/12C07C227/20C07C253/30A61K31/495A61K31/216A61K31/167A61K31/165A61K31/407A61K31/40A61K31/498A61K31/277A61P3/10
CPCC07C229/34C07C237/20C07C255/29C07C2601/14C07D207/08C07D241/04C07D241/42C07D295/192C07D487/04
Inventor 张孝清宋志春包金远蒋玉伟
Owner NANJING HUAWE MEDICINE TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap